Contemporary use of <scp>guideline‐based</scp> higher potency <scp>P2Y12</scp> receptor inhibitor therapy in patients with <scp>moderate‐to‐high</scp> risk <scp>non‐ST‐segment</scp> elevation myocardial infarction: Results from the Canadian <scp>ACS</scp> reflective <scp>II cross‐sectional</scp> study
Clinical cardiology